Answers are grounded in this paper and cite their sources.
OBJECTIVES: Denosumab is often employed as a long-term therapy for treating patients with osteoporosis. Yet, scant data are available on the safety and efficacy of denosumab use beyond 10 years. Our objective was to retrospectively analyze our experience using denosumab for osteoporosis treatment in a real-world setting to provide efficacy and safety data, especially when used beyond a decade. METHODS: A retrospective analysis was performed of 4030 patients treated for osteoporosis with denosumab as part of routine rheumatology care. Patients with long-term use (n=750) were selected, as defined by ≥5 years cumulative exposure. This group was then stratified into those receiving ≥10-year cumulative exposure (n=400) and a reference group with exposure for 5-10 years (n=350), a duration established to be safe and effective from prior studies. Efficacy of denosumab was determined by analyzing sequential BMD. Safety was determined through chart review. Safety concerns of special interest, namely osteonecrosis of jaw and atypical femur fractures, were described in detail. RESULTS: 400 patients were identified with extended denosumab exposure ≥10 years. For these patients, BMD increased steadily with no evidence of plateau and surpassed the total hip surrogate thresholds associated with reduced fracture risk. Among safety concerns of special interest, we observed 18 cases of ONJ and 2 cases of AFF from the entire cohort, with no temporal relationship to duration of use. CONCLUSIONS: Based on our experience, we conclude that there is no evidence-based rationale for discontinuing denosumab after 10 years; rather, prolonged use appears to remain both safe and effective.
No takes yet. Share an insight, caveat, or question.
Gruber et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: